BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Skin cancer AND LDH AND Diagnosis
116 results:

  • 1. Characteristics of long-survivor metastatic melanoma after polychemotherapy and interferon: a retrospective study.
    Py C; De Vito C; Tsantoulis P; Kaya G; Labidi-Galy SI; Dietrich PY
    Swiss Med Wkly; 2023 Dec; 153():3504. PubMed ID: 38579317
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Size selection of intrahepatic lesions for cryoablation contributes to abscopal effect and long-term survival in patients with liver metastatic melanoma receiving PD-1 blockade therapy.
    Shen L; Tan H; Nie J; Jiang Y; Nuerhashi G; Qi H; Cao F; Wen C; Chen S; Zhang T; Zheng W; Liu P; Liu Y; Huang T; Li D; Zhang X; Fan W
    Cancer Immunol Immunother; 2024 Mar; 73(4):68. PubMed ID: 38430269
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. A single-center retrospective analysis of prognoses in patients with melanoma brain metastases and effectiveness of treatment in Japan.
    Wada S; Ogata D; Kashihara T; Okuma K; Eto H; Nakano E; Takahashi A; Namikawa K; Igaki H; Yamazaki N
    Cancer Med; 2023 Dec; 12(24):21933-21943. PubMed ID: 38083908
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Systemic therapy timing and use in patients with advanced melanoma at the end of life: A retrospective cohort study.
    van Lith PEA; Schreuder K; Jalving M; Reyners AKL; Been LB; Rácz E; Fransen HP; Louwman MWJ
    J Dermatol; 2024 Apr; 51(4):584-591. PubMed ID: 38078557
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis.
    Piulats JM; Watkins C; Costa-García M; Del Carpio L; Piperno-Neumann S; Rutkowski P; Hassel JC; Espinosa E; de la Cruz-Merino L; Ochsenreither S; Shoushtari AN; Orloff M; Salama AKS; Goodall HM; Baurain JF; Nathan P
    Ann Oncol; 2024 Mar; 35(3):317-326. PubMed ID: 38048850
    [TBL] [Abstract] [Full Text] [Related]  

  • 6.
    Huang X; Chen L; Sha T; Lin Y; Zeng R; Xu J; Chen S; Cai HH; Zhang J; Zhou H; Sun PH; Jiang X
    ACS Nano; 2023 Oct; 17(20):20073-20086. PubMed ID: 37792448
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Assessing the prognostic value of IMDC risk score for nivolumab-treated patients with renal cancer and malignant melanoma.
    Beypınar I; Sözel Y; Önder AH
    Cancer Biomark; 2023; 38(3):367-377. PubMed ID: 37718781
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Causes of Death in Cutaneous T-Cell Lymphoma Patients.
    Lebas E; Collins P; Somja J; Nikkels AF
    Dermatology; 2023; 239(6):860-867. PubMed ID: 37611553
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Outcomes in patients with
    Aglietta M; Chiarion-Sileni V; Fava P; Guidoboni M; Depenni R; Minisini A; Consoli F; Ascierto PA; Rinaldi G; Banzi M; Marconcini R; Gueli R; Ferraresi V; Tucci M; Tonini G; Lo Re G; Guida M; Del Vecchio M; Marcon IG; Queirolo P
    Tumori; 2023 Dec; 109(6):537-545. PubMed ID: 37417313
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. CD30 expression in cutaneous B-cell lymphomas.
    Afolayan-Oloye O; Zhao L; Tejasvi T; Chan MP; Harms PW; Fullen DR; Wilcox RA; Hristov AC
    J Cutan Pathol; 2023 Sep; 50(9):819-827. PubMed ID: 37290910
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Differences in glucose metabolic activity in liver metastasis separates two groups of metastatic uveal melanoma patients with different prognosis.
    Del Carpio LP; Algarra MA; Sabaté-Llobera A; Rodriguez-Vida A; Rossi-Seoane S; Ruiz S; Leiva D; Ramos E; Lladò L; Lorenzo D; Gutierrez C; Cortes-Romera M; Caminal JM; Piulats JM
    Cancer Med; 2023 Jul; 12(13):14062-14071. PubMed ID: 37211960
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG.
    Franklin C; Mohr P; Bluhm L; Meier F; Garzarolli M; Weichenthal M; Kähler K; Grimmelmann I; Gutzmer R; Utikal J; Terheyden P; Herbst R; Haferkamp S; Pfoehler C; Forschner A; Leiter U; Ziller F; Meiss F; Ulrich J; Kreuter A; Gebhardt C; Welzel J; Schilling B; Kaatz M; Scharfetter-Kochanek K; Dippel E; Nashan D; Sachse M; Weishaupt C; Löffler H; Gambichler T; Loquai C; Heinzerling L; Grabbe S; Debus D; Schley G; Hassel JC; Weyandt G; Trommer M; Lodde G; Placke JM; Zimmer L; Livingstone E; Becker JC; Horn S; Schadendorf D; Ugurel S
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37028819
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Staging lymph nodes and blood at diagnosis in mycosis fungoides identifies patients at increased risk of progression to advanced stage: A retrospective cohort study.
    Allen PB; McCook-Veal AA; Switchenko JM; Paulino DM; Niyogusaba T; Baird KM; Tarabadkar ES; Lechowicz MJ
    Cancer; 2023 Feb; 129(4):541-550. PubMed ID: 36523150
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Changes in outcomes and factors associated with survival in melanoma patients with brain metastases.
    Hasanov M; Milton DR; Davies AB; Sirmans E; Saberian C; Posada EL; Opusunju S; Gershenwald JE; Torres-Cabala CA; Burton EM; Colen RR; Huse JT; Glitza Oliva IC; Chung C; McAleer MF; McGovern SL; Yeboa DN; Kim BYS; Prabhu SS; McCutcheon IE; Weinberg JS; Lang FF; Tawbi HA; Li J; Haydu LE; Davies MA; Ferguson SD
    Neuro Oncol; 2023 Jul; 25(7):1310-1320. PubMed ID: 36510640
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma.
    Ruggiero CF; Fattore L; Terrenato I; Sperati F; Salvati V; Madonna G; Capone M; Valenti F; Di Martino S; Mandoj C; Liguoro D; Castaldo V; Cafaro G; Simeone E; Vanella V; Russillo M; Conti L; Cuda G; Giannarelli D; Ascierto PA; Mancini R; Ciliberto G
    Theranostics; 2022; 12(17):7420-7430. PubMed ID: 36438490
    [No Abstract]    [Full Text] [Related]  

  • 16. Predictors of large cell transformation in patients with Sezary Syndrome-A retrospective analysis.
    Jairath NK; Bardhi R; Runge JS; Bledea R; Jairath R; Wang Y; Patrick M; Wilcox RA; Hristov AC; Tsoi LC; Tejasvi T
    PLoS One; 2022; 17(11):e0277655. PubMed ID: 36383618
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. High serum ldh and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy.
    Dercle L; Ammari S; Roblin E; Bigorgne A; Champiat S; Taihi L; Plaian A; Hans S; Lakiss S; Tselikas L; Rouanne M; Deutsch E; Schwartz LH; Gönen M; Flynn J; Massard C; Soria JC; Robert C; Marabelle A
    Eur J Cancer; 2022 Dec; 177():80-93. PubMed ID: 36332438
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Chemotherapy induced juvenile dermatomyositis: a novel presentation- a case report.
    Vagha K; Akhil CVS; Madirala S; Varma A; Lakra M; Vagha J
    BMC Pediatr; 2022 Oct; 22(1):623. PubMed ID: 36316673
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. A distinct four-value blood signature of pyrexia under combination therapy of malignant melanoma with dabrafenib and trametinib evidenced by an algorithm-defined pyrexia score.
    Schaefer H; Rübben A; Esser A; Araujo A; Persa OD; Leijs M
    PLoS One; 2022; 17(8):e0273478. PubMed ID: 36006943
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Immune checkpoint inhibitors-associated thrombosis in patients with lung cancer and melanoma: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group.
    Cánovas MS; Garay DF; Moran LO; Pérez JR; Rubio CMG; de Mena ML; Portero BO; Castro JB; Lage Y; Lavin DC; Blanco ABR; de Soignie AMMF; Perejón JZB; Colomo LJ; Boluda NB; Moreno JB; Verduguez TQ; Garrido CR; Huertas RM; Puig CFI; Martín AJM
    Clin Transl Oncol; 2022 Oct; 24(10):2010-2020. PubMed ID: 35668339
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 6.